Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Global Cord Blood Corp. operates as a holding company, which engages in providing cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. It provides parents of newborn infants with umbilical cord blood storage services. The company was founded on January 17, 2008 and is headquartered in Hong Kong.

HONG KONG, July 29, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed.

Global Cord Blood Corporation Files Its Annual Report on Form 20-F

Global Cord Blood Corporation (CO) CEO Tina Zheng on Q4 2020 Results - Earnings Call Transcript

Banco BBVA Argentina SA

Garrett Motion

Information Services Group

Mistras Group

Newmark Group

Office Depot

Orion Energy Systems

Smith Micro Software

Silvercorp Metals

When looking for penny stocks to buy under $5, you’ve got to go dumpster diving. That’s never an easy task when stocks aren't cheap.

10 Penny Stocks to Buy Under $5 That Might Be Worth the Risk

Bio-Rad Laboratories

Fonar

As investors continue grappling with coronavirus fears, three medical companies with high financial strength and trading below Peter Lynch’s valuation line of 15 times earnings are Bio-Rad Industries Inc.

3 Medical Companies With the Strength to Weather Coronavirus Fears

Shares of Global Cord Blood Corp. CO, -0.61% were up 0.2% in premarket trading on Friday after the Hong Kong-based company said it expects a negative impact to its fourth-quarter performance due to COVID-19, the new coronavirus that has sickened at least 48,000 people, primarily in China.

Global Cord Blood's stock rises as it predicts coronavirus impact

Global Cord Blood Corporation (CO) CEO Tina Zheng on Q2 2020 Results - Earnings Call Transcript

Global Cord Blood Corporation (CO) Management on Q1 2020 Results - Earnings Call Transcript

Global Cord Blood Corporation (CO) Management on Q4 2019 Results - Earnings Call Transcript

Cordlife is proposing to merge with Global Cord Blood in what effectively is a reverse merger and a way to list Global Cord Blood on the Singaporean stock exchange.

Cordlife Deal On Global Cord Blood Could Be Catalyst For ~100% Valuation Appreciation

News for Global Cord Blood Stock (CO)